The role of dihydrotestosterone in benign prostatic hyperplasia.
about
5alpha-reductase: history and clinical importanceApoptotic Pathways Linked to Endocrine System as Potential Therapeutic Targets for Benign Prostatic HyperplasiaCurrent opinion on the role of testosterone in the development of prostate cancer: a dynamic modelHuman prostate fibroblasts induce growth and confer castration resistance and metastatic potential in LNCaP CellsCurrent status of 5alpha-reductase inhibitors in the management of lower urinary tract symptoms and BPH.Effect of dihydrotestosterone on mouse embryonic stem cells exposed to H2O2-induced oxidative stressHistochemical evaluation of human prostatic tissues with Cratylia mollis seed lectinThe potent synthetic androgens, dimethandrolone (7α,11β-dimethyl-19-nortestosterone) and 11β-methyl-19-nortestosterone, do not require 5α-reduction to exert their maximal androgenic effects.Understanding extranuclear (nongenomic) androgen signaling: what a frog oocyte can tell us about human biologyInhibitory effect of Yukmijihwang-tang, a traditional herbal formula against testosterone-induced benign prostatic hyperplasia in rats.Effects of 5-alpha reductase inhibitors on erectile function, sexual desire and ejaculation.Relationship Between Second to Fourth Digit Ratios and Benign Prostatic Hyperplasia in Aging MenInfluence of Panax ginseng on Alpha-Adrenergic Receptor of Benign Prostatic Hyperplasia.Novel drug targets for the pharmacotherapy of benign prostatic hyperplasia (BPH).Androgens and estrogens in benign prostatic hyperplasia: past, present and future.Androgen deprivation induces rapid involution and recovery of human prostate vasculatureInhibitory effect of curcumin on testosterone induced benign prostatic hyperplasia rat model.Spatial Localization and Quantitation of Androgens in Mouse Testis by Mass Spectrometry ImagingTestosterone replacement therapy for male hypogonadism: part III. Pharmacologic and clinical profiles, monitoring, safety issues, and potential future agents.Medical and minimally invasive therapies for the treatment of benign prostatic hyperplasia.The effect of benign lower urinary tract symptoms on subsequent prostate cancer testing and diagnosisManaging the progression of lower urinary tract symptoms/benign prostatic hyperplasia: therapeutic options for the man at risk.Inhibitory Effect of Yongdamsagan-Tang Water Extract, a Traditional Herbal Formula, on Testosterone-Induced Benign Prostatic Hyperplasia in RatsCinnamomi Cortex (Cinnamomum verum) Suppresses Testosterone-induced Benign Prostatic Hyperplasia by Regulating 5α-reductase.Finasteride in the treatment of patients with benign prostatic hyperplasia: a reviewSeoritae extract reduces prostate weight and suppresses prostate cell proliferation in a rat model of benign prostate hyperplasia.Effects of D-004, a lipid extract from Cuban royal palm fruit, on inhibiting prostatic hypertrophy induced with testosterone or dihydrotestosterone in a rat model: A randomized, controlled studyIn vitro effect of D-004, a lipid extract of the fruit of the cuban royal palm (Roystonea regia), on prostate steroid 5α-reductase activity.Effect of Benincasa hispida fruits on testosterone-induced prostatic hypertrophy in albino rats.Effects of D-004, a lipid extract of the fruit of the Cuban royal palm (Roystonea regia) or the lipidosterolic extract of saw palmetto (Serenoa repens) on the sexual activity in male rats: A controlled, experimental study.BPH and prostate cancer risk.Finasteride metabolism and pharmacogenetics: new approaches to personalized prevention of prostate cancer.Investigational therapies targeted to the treatment of benign prostatic hyperplasia.In vivo evaluation of hot water extract of Acorus gramineus root against benign prostatic hyperplasia.Prostatic Artery Embolization (PAE) for Symptomatic Benign Prostatic Hyperplasia (BPH): Part 2, Insights into the Technical Rationale.Inhibitory Activities of Phenolic Compounds Isolated from Adina rubella Leaves Against 5α-Reductase Associated with Benign Prostatic Hypertrophy.5α-Reductase Inhibitors for Treatment of Benign Prostatic Hyperplasia: A Systematic Review and Meta-Analysis.Endocrine control of benign prostatic hyperplasia.Serum testosterone as a biomarker for second prostatic biopsy in men with negative first biopsy for prostatic cancer and PSA>4ng/mL, or with PIN biopsy resultDiastereomers of the brominated flame retardant 1,2-dibromo-4-(1,2 dibromoethyl)cyclohexane induce androgen receptor activation in the hepg2 hepatocellular carcinoma cell line and the lncap prostate cancer cell line
P2860
Q24546176-CF7E820F-3524-4763-A662-CA0A0CF8B11BQ26741226-93E9B0EA-F0B1-43AE-AB7F-FA640E50621EQ26778886-8B46E03F-EB3D-4240-B41F-074BD5CD53E1Q30431576-60143EFA-B8B6-4413-9DB3-01AA03D0E630Q33602452-EE05DE6F-A5D7-4761-82DE-2F928EE901B9Q33612390-3FE27BD5-A882-41A2-A56B-B0D9F1F1ED76Q33959922-5D5D7C16-E797-4659-B249-73B8E81CD6CFQ34124042-EC2087BD-1A93-4EC9-9C48-C701BA205C53Q34167106-694A58ED-16EC-4268-9EEC-391024F225DAQ34240687-17E42F74-769D-40D9-B09C-86AB56AAB42CQ34313221-919138F0-229E-487E-AA5C-F0CC92163377Q34484103-7CF5A4E6-B43B-4448-9EE0-1A3995248BC6Q34791930-E86D5A1A-920E-4A98-A70B-38477FD91385Q35089850-829B5FB9-1041-4903-B859-070B74D19BEFQ35231660-CADEFCE4-7BEC-4668-9ACC-A5A0623BFBA9Q35760385-441DA3B2-CA2D-48A8-B54F-EC4490A33937Q35816835-4B9FF555-B6CE-4302-9447-9D9E778BBE73Q36145939-C47FAEF6-4900-4626-B1E6-8F2558B41786Q36271731-BB323FF1-A1B5-42E2-BBC6-FCF01F2E4EE5Q36498032-CDFED2BE-B6AA-4AC6-8164-90C1133355E2Q36799711-D85A6C0B-2388-45A6-83BA-B599543DD4B3Q36872815-EE70B819-1942-4159-B4BA-4A998CABDE19Q37140727-24E7D5FC-73FC-40ED-B681-D80B3F0F0DA7Q37195621-136BFF14-169D-46E0-9822-5BAD1AC601F1Q37261063-09BE0506-EE7B-4C3A-879C-2279AFB18AECQ37631419-8BBBE179-3485-4F54-A975-D6FFE1090935Q37661055-56F6C400-391E-4DDD-B014-8277C60C783DQ37663475-8B2770BA-884C-44D7-B55C-DBBAFBEFCBFDQ37672053-EB771056-2F74-46A9-B53F-F90C7A6EE916Q37672774-2187B10F-37E5-4DA6-B8CE-DF78C588FB1BQ37707775-D022D678-46D9-4978-A702-0BDE40425CBEQ37818297-D66676E5-A6DE-44E7-98FA-7FE9BEC596BDQ38073830-58F86D25-C7D4-4D96-8050-80C00DCD918DQ38399536-0B6187F1-7673-4263-B3A6-A075481D0927Q38631990-8BAE43E7-ACB0-42E0-A461-DB18ED04D4D9Q38758864-8FA84AD4-3195-4DCE-AE88-DF29A1C40EB3Q38795176-9DEFB676-DED7-4C93-85D4-75FA08310B4AQ38811041-A54D5106-4396-4F16-BEAA-C8891EF34E92Q39483117-D3F8EDCA-951B-449A-8493-5F6E011B85AEQ39756037-64518A6E-B4F2-452F-895B-1329D9EACA23
P2860
The role of dihydrotestosterone in benign prostatic hyperplasia.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
The role of dihydrotestosterone in benign prostatic hyperplasia.
@en
The role of dihydrotestosterone in benign prostatic hyperplasia.
@nl
type
label
The role of dihydrotestosterone in benign prostatic hyperplasia.
@en
The role of dihydrotestosterone in benign prostatic hyperplasia.
@nl
prefLabel
The role of dihydrotestosterone in benign prostatic hyperplasia.
@en
The role of dihydrotestosterone in benign prostatic hyperplasia.
@nl
P1433
P1476
The role of dihydrotestosterone in benign prostatic hyperplasia.
@en
P2093
Culley Carson
Roger Rittmaster
P356
10.1016/S0090-4295(03)00045-1
P407
P433
P577
2003-04-01T00:00:00Z